News Hub | News Direct

MGC Pharmaceuticals delivers its largest-ever order

MGC Pharmaceuticals Ltd

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 08, 2022 08:46 AM Eastern Standard Time

Video

AiViva Says Its AIV001 Shows Potential Promise To Treat Post-Surgical Incisional Scarring And Keloids

AiViva BioPharma

Interested in investing in AiViva’s campaign? Click here to get started! Scarring can have negative physical, aesthetic, and psychological effects if left untreated. A growing awareness of treatment options and technological advancements has given its treatment industry adoption a boost. Scars result from injuries, surgeries, illness, burns and acne. Scars form on your skin or inside your body when one heals an injury or trauma. Our body’s wound healing process can cause the overproduction of collagen, a protein found in the dermis or second layer of the skin, resulting in raised lumpy scarring or keloids. Keloids tend to grow larger over time and in some cases, reappear after treatment. A scar never completely goes away. When it comes to scarring, where it occurs matters. A wound in an area that moves, like your elbow and knee, is more likely to scar. A scar on the face would be harder to heal because one’s face is constantly exposed to the environment. The Growing Market For Scar and Keloid Treatments The keloid and scar treatment market is burgeoning. One reason for this could be an increasing number of accidents, surgeries, and other injuries around the world each year. The combined hypertrophic and keloid scar treatment global market was valued at $6.34 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 8.47% from 2022 to 2030. Companies like Sanoma Pharmaceuticals (NASDAQ: SNOA) are partnering with e-commerce sites like Amazon.com Inc. (NASDAQ: AMZN) to provide hypertrophic and keloid scar treatment products in the U.S. Partnerships like this are also expected to drive the retail pharmacy segment. There are reportedly no approved drugs on the market for the prevention of scars following surgery. The appearance of scar may be improved by laser therapy, steroid injections, or silicon sheets. Dermatologists and plastic surgeons may surgically remove a scar to restore function of a body part that may have been restricted by the scar. Keloid scars are difficult to get rid of and tend to return after treatment in a majority of cases. Current treatments for keloids include steroidal injections at the scar site, cryosurgery (freezing), keloidectomy (surgical removal), pressure dressings, silicone sheeting and gels and radiation. While each of these treatment options by themselves, or when combined with others, could help by treating and improving physical appearance and skin sensitivity issues such as itch and pain, a scar never goes away. How AiViva’s AIV001 Treatment Could Address Scar Formation AIV001 is a compound that could address the negative impacts of scarring. AIV001 has been found to be effective in modulating inflammation and scarring of the skin as well as reducing neovascularization (cell proliferation) associated with some cancers, according to AiViva. The company says it has seen positive signals from its phase I clinical trial of AIV001 for incision-based dermal scarring and wound healing. Trial results showed that AIV001 was safe and well tolerated in the local intradermal treatment of incisional wounds and reduced fibrosis through only a single dose with no systemic side effects observed in humans. These results suggest that the intradermal AIV001 treatment could potentially have significant clinical utility by modulating the aberrant scarring associated with fibrosis during the wound-healing process. “Scarring has been a significant issue that can cause debilitating aesthetic, functional and psychological effects. There are no (Food and Drug Administration) FDA-approved therapeutics for the treatment of post-operative scars, therefore, AIV001 has the potential to be a transformative treatment in this space,” AiViva CEO Diane Tang-Liu said. About AiViva Biopharma: AiViva Biopharma, is a clinical stage biotech company founded in 2015 by four pharmaceutical industry veterans with more than 300 years of combined industry experience. AiViva's founders have demonstrated a successful track record across the full spectrum of drug development and commercialization, in addition to raising capital, and IPOs on the NYSE and NASDAQ.AiViva was formed with the mission of developing novel, innovative pharmaceutical products through an efficient, risk-mitigated development strategy to address major unmet medical needs. The company has raised over $30 million in capital so far, including over $10 million raised in 2022. AiViva was rated as a top 20 clinical-stage biopharma company by Life Sciences Review in 2022. Interested in investing in AiViva? Click here. If you would like to learn more about AiViva, check out its website. AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ. The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. Contact Details Michael office@aiviva.com Company Website https://aiviva.com/

December 08, 2022 08:00 AM Eastern Standard Time

Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive

Unicycive Therapeautics, Inc.

In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount to providers of dialysis services. In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023. The ESRD PPS, often referred to as “the bundle”, is the government-funded program that pays for renal dialysis services and certain prescription drugs for patients with late-stage chronic kidney disease (CKD). A category of drugs called phosphate binders that dialysis patients need to be able to control a severe complication of their disease known as hyperphosphatemia is currently not covered under the ESRD PPS. Therefore, dialysis patients currently resort to sourcing their phosphate binders through prescription drug plans run by for-profit insurance companies, a process which is fraught with challenges due to these branded prescriptions being more expensive and difficult to access. In the 2023 Final Rule, the CMS commented on its intention to include phosphate binders in the bundle, stating that the addition of phosphate binders would “mitigate the risk of potential access issues for minority populations, which include African-American/Black, Asian, Hispanic, and Other non-white populations, promote health equity for patients that lack Medicare Part D coverage or have coverage less generous than the Part D standard benefit, and contribute to better clinical outcomes by leveling the playing field for all patients with ESRD”. This change is slated to be implemented in 2025 through the TDAPA (transitional drug add-on payment adjustment) –- a direct government payment program that takes the reimbursement process out of the hands of private insurance companies. During a minimum 2-year TDAPA period starting in 2025, CMS will evaluate the additional cost of adding phosphate binders into the PPS “bundle” and then make the change permanent. CMS’s goal in this planned change to phosphate binder reimbursement is to “result in better drug therapy management for the ESRD beneficiary, and to improve their access to these medications”. This development could be great news for Unicycive Therapeutics Inc. (NASDAQ: UNCY). The company is developing what they believe to be a best-in-class phosphate binder they hope to get approved by the FDA in 2024. The company is developing an investigational new drug called Renazorb TM (lanthanum dioxycarbonate that binds and eliminates phosphate in the gastrointestinal tract. Renazorb utilizes a proprietary nanoparticle technology being developed by Unicycive for the treatment of hyperphosphatemia in CKD patients on dialysis. Unicycive says that it has completed a clinical trial studying Renazorb in 32 healthy volunteers with encouraging results – as per the study Renazorb was minimally absorbed into the systemic circulation and was safe and well-tolerated at doses up to 6000 mg/day. Renazorb was found to significantly reduce urine phosphate excretion and significantly increase fecal phosphate excretion at doses at and above 3000 mg/day. The company says that Renazorb offers potential advantages over the most commonly used phosphate binder – Renvela – because it dramatically reduces the number and size of pills that patients are required to take. Many people suffering from CKD are weighed down by a high pill burden due to their various other comorbidities that require taking multiple pills. This leads to patients neglecting to take their medication because they are overwhelmed by the number and size of the pills they must take. Unicycle says that the efficiency and smaller size of Renazorb pills could reduce the pill burden for these patients by 3 to 4 fold. Renazorb also has an added convenience for patients since it is swallowed with water instead of having to be chewed. Renazorb is protected by patents in the U.S. and other countries outside the U.S. including Canada, Europe, Japan, China, and Australia, with validity until 2031. “Gaining early patient access and reimbursement for newly launched branded drugs can be a challenge” stated Doug Jermasek, Executive Vice President at Unicycive. “For-profit insurance plans often restrict access to new drugs or impose very high patient copays. Beginning in 2025, and coinciding with the expected launch of our promising new medicine, these barriers will be removed for patients and their healthcare providers. We are excited by the potential to launch RENAZORB into this new environment of expanded patient access.” Unicycive is also developing a drug for the treatment of acute kidney injury – namely UNI 494 – for which the company is filing to begin Phase 1 human trials. Other companies developing drugs for the treatment of CKD include Ardelyx Inc. (NASDAQ: ARDX), Akebia Therapeutics Inc. (NASDAQ: AKBA), and Cara Therapeutics. ( NASDAQ: CARA). To learn more about Unicycive visit its website. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

December 08, 2022 08:00 AM Eastern Standard Time

'Tis the Season-ally Inspired Holiday Menus at Firebirds Wood Fired Grill

500NewsWire

Charlotte, NC ( 500NewsWire ) -- Firebirds Wood Fired Grill introduces new holiday lunch and dinner menus just in time to make any celebration a memorable one this holiday season. From hand-cut wood-fire grilled NY Strip, and certified Duroc pork chop with cognac cream sauce, to Bananas Foster Bread Pudding for dessert, Firebirds’ limited time scratch-made menus are available now through January 3. Firebirds Wood Fired Grill is known for its signature hand-cut steaks and fresh seafood hand-fileted in-house and seared over locally sourced hickory, oak, or pecan wood on Firebirds’ exposed wood-fired grill. Firebirds’ seasonal Lunch Menu includes suggested wine pairings, and features: NY Strip (10oz.) BLT butter / choice of side Suggested wine pairing: Decoy Cabernet Sauvignon Parmesan Crusted Mahi Coal-roasted tomato-basil sauce / “loaded “ember-grilled corn / fresh asparagus Suggested wine pairing: Decoy Chardonnay Lump Crab Cakes Bold remoulade / wonton slaw / seasoned steak fries Suggested wine pairing: Firebirds Private Label Chardonnay Guests can enhance their entrées by adding: Lump Crab Cake Lobster Mac & Cheese Dessert Bananas Foster Bread Pudding Vanilla bean ice cream / spiced pecans / crispy cinnamon-sugar tortilla Firebirds’ seasonal Dinner Menu includes suggested wine pairings, and features: NY Strip (14oz.) BLT butter / choice of side Suggested wine pairing: Decoy Cabernet Sauvignon Tomahawk Prime Pork Chop Wood-grilled, certified Duroc pork chop / cognac cream sauce / red wine-poached apples / green chile mac & cheese Suggested wine pairing: Acrobat Pinot Noir Parmesan Crusted Mahi Coal-roasted tomato-basil sauce / “loaded “ember-grilled corn / fresh asparagus Suggested wine pairing: Decoy Chardonnay Lump Crab Cakes Bold remoulade / wonton slaw / seasoned steak fries Suggested wine pairing: Firebirds Private Label Chardonnay Guests can enhance their entrees by adding: Lump Crab Cake Lobster Mac & Cheese Dessert Bananas Foster Bread Pudding Vanilla bean ice cream / spiced pecans / crispy cinnamon-sugar tortilla Many of the restaurant’s dishes are created using fresh seasonal ingredients. Gluten-sensitive menu items, such as Grilled Tenderloin Salad, Wood Grilled Salmon, and Parmesan Mashed Potatoes, are also available. Firebirds offers catering, online ordering for ToGo and delivery options. In addition, Firebirds is offering a holiday gift card promotion. For every $100 in gift cards purchased in-store or online, guests will receive $20 in “bonus cards.” This special offer is available now through December 31st and “bonus cards” are valid for redemption from January 1 through February 9, 2023. For more information visit firebirdsrestaurants.com/gift-cards/. Firebirds Wood Fired Grill’s FIREBAR® offers an impressive array of seasonal cocktails, craft beer, bourbon, after-dinner drinks, Firebirds’ private label wine, hand crafted mocktails and more. Popular specialties include Wine Down Mondays, and happy hour in the FIREBAR® and on the Patio every Monday through Friday from 4PM – 7PM. Happy Hour times vary. Visit FirebirdsRestaurants.com to make a reservation, order ToGo online, or register to become a member of Firebirds’ Inner Circle and be the first to hear about upcoming events, promotions, new menu items and exclusive offers. Members receive a gift for joining and a gift for their birthday. About Firebirds Wood Fired Grill Firebirds Wood Fired Grill, a polished casual American restaurant, is an energetic twist on the traditional grill featuring a boldly flavored menu in a stylish, fire-centric atmosphere. Signature menu items include hand-cut steaks and fresh seafood hand-fileted in-house and seared over locally sourced hickory, oak, or pecan wood on Firebirds’ exposed wood-fired grill. Complementing its inviting dining room, a patio with seasonal comforts and the award-winning FIREBAR® are additional gathering spaces inside the restaurant. Firebirds has been named one of ten ‘Breakout Brands’ by Nation’s Restaurant News, and the 2022 Diners’ Choice Winner awarded by OpenTable. Firebirds supports sustainability efforts and partners with Alex’s Lemonade Stand Foundation, having surpassed $3 million raised for childhood cancer research through the sale of fresh-squeezed lemonade. To become a member of Firebirds Inner Circle, order ToGo online or to make a reservation visit firebirdsrestaurants.com. Contact Details Firebirds Wood Fired Grill Lesley Gamwell +1 404-309-6915 lgamwell@rountreegroup.com Company Website https://firebirdsrestaurants.com/

December 07, 2022 08:59 AM Eastern Standard Time

A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial

Enlivex Therapeutics, Ltd.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. The cleared amendments also allow Enlivex to use a newly developed frozen formulation of Allocetra TM — the macrophage reprogramming immunotherapy it’s evaluating as a potential sepsis treatment in the clinical trial. The Current Standard Of Care For Sepsis Needs Improvement Each year, about 1.7 million U.S. adults develop sepsis in response to an infection. Of those, about 350,000 will die from septic shock, according to the Centers for Disease Control (CDC). Despite the risks of sepsis, there is currently no specific treatment for the life-threatening condition. That’s because it’s not a pathogen in its own right but an extreme response to an infection the patient already has. That underlying infection can be bacterial, fungal or viral so treating sepsis often starts with identifying the underlying infection and administering the appropriate antibiotic, antimicrobial or antiviral treatment. This initial treatment, along with intravenous fluids and vasopressors to maintain organ function and blood pressure, forms the current standard of care, but they’re really just a way of keeping the patient alive while their immune system, hopefully, fights the infection causing the sepsis response. Even with this standard of care, timing is everything. In a study of New York State Department of Health data, researchers found that for each hour antibiotic treatment was delayed in patients with sepsis, the risk of mortality increased by 4%. In other words, patients need to receive treatment as soon as possible to increase the odds of survival. This large unmet need has motivated many pharmaceutical companies to explore new treatment options, but so far, few have shown significant promise. For example, monoclonal antibodies (mAbs), like Merck & Co. Inc. ’s (NYSE: MRK) bezlotoxumab or Aridis Pharmaceuticals Inc. ’s (NASDAQ: ARDS) tosatoxumab, have made some headway, but these are engineered to target specific infections. So doctors would need to identify the specific mAb to use and hope that one exists for that particular infection, which is not a guarantee since mAbs are still relatively new. Enlivex’s Allocetra Is An Immunotherapy That Could Rebalance The Immune Response At its core, sepsis is an extreme immune response to an infection in the body. That’s why Enlivex has chosen to explore immunotherapy options for treating the condition. Allocetra TM, it’s leading drug candidate, works by reprogramming macrophages from healthy donor cells to help the patient’s own macrophages return to their homeostatic state of stability. Macrophages are a type of immune cell that circulates throughout the body, monitoring for signs of infection. When a pathogen is spotted, they immediately “eat” it and send out an alarm signal to the rest of the immune system. Certain conditions, like sepsis, can disrupt macrophages, triggering an excessive inflammatory response that can end up causing the organ damage and organ failure that make sepsis so life-threatening. Allocetra’s formula uses donor macrophages that have been programmed to send out an “eat me” signal to the host’s macrophages. Once engulfed, the donor cells then reprogram those host macrophages to return to their homeostatic state. In the preclinical and clinical trials Enlivex has completed so far, that return to homeostasis has resulted in reduced mortality and improved sequential organ failure assessment (SOFA) scores, suggesting that the immunotherapy could help moderate the immune response and protect organs from damage and failure. While antimicrobials will still be necessary for fighting the underlying infection, Allocetra’s ability to influence the host’s overactive immune response could become an essential tool for preventing long-term damage and reducing mortality rates. The Phase II Clinical Trial Will Include An Expanded Patient Population And A More Shelf-Stable Version Of Allocetra Initially, the Phase II trial was limited to patients with pneumonia-associated sepsis. With the recent amendments cleared by Israel, Spain and Greece, Enlivex is now able to expand the trial to include patients with sepsis related to biliary, urinary tract and peritoneal infections. The amendments also clear the way for the clinical-stage immunotherapy company to treat patients in the trial with its newer frozen formulation of Allocetra. In development for the last two years, frozen Allocetra is expected to have a shelf life spanning years rather than the 96-hour shelf life of the liquid version. A longer shelf life means Enlivex can manufacture the novel immunotherapy at scale and hospitals can keep it in stock so that it’s readily available for rapid deployment for the treatment of sepsis patients. Enlivex plans to submit these same protocol amendments in other jurisdictions in hopes of further expanding its Phase II research. But with the regulatory clearance achieved so far, the company is optimistic that it can shorten the timeline to potential approval of frozen Allocetra as a sepsis treatment, which could move up the date of a possible commercial launch. As part of a new generation of companies representing the future of cell therapy – off-the-shelf, highly scalable and low COGS “beyond CAR-T” cell therapies – Enlivex is focused on a highly differentiated novel immunotherapeutic mechanism – macrophage homeostasis. Macrophage homeostasis is severely disrupted by certain diseases states, and such imbalance is critical to the progression of the diseases. Allocetra has the potential to introduce highly-effective, low-cost allogeneic cell therapies for life-threatening clinical indications that are defined as "unmet medical needs", including sepsis – one of the leading causes of mortality, and oncology, through restoration of macrophage homeostasis. Enlivex is led by a seasoned management team who founded PROLOR Biotech and led it to a successful $560 financial exit and a partnership with Pfizer. PROLOR’s lead product, now named NGenla® by Pfizer, recently received marketing approval in Australia, Canada, Japan and the EU. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. Contact Details Shachar Shlosberger shachar@enlivexpharm.com Company Website https://enlivex.com

December 07, 2022 08:40 AM Eastern Standard Time

The Vaccine Group completes two deadly disease vaccination projects

Frontier IP Group PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 07, 2022 08:24 AM Eastern Standard Time

Video

CleverTap Unveils RenderMax

CleverTap

CleverTap, the World's #1 Retention Cloud today unveiled RenderMax – a proprietary technology that can increase mobile push notification render rates up to 90% on low-end Android devices. Push notifications have the power to increase customer retention rates anywhere from 3 - 10 times. Most marketers just focus on their push notification delivery rates, but a “delivered" notification that doesn't render on the user’s device is a wasted effort. For those who equate delivery and rendering as equal, render rate is the percentage of the number of push notifications the end user received (and were rendered) on the user’s device compared to the total number of push notifications that were sent. All Chinese OEM devices use a custom variant of the stock Android OS. To optimize battery consumption, these OS variants are configured to bypass the Google/Firebase push delivery service, resulting in low delivery rates and even lower render rates. RenderMax gives CleverTap customers a significant competitive advantage as they can now engage users they could not before and elevate the ROI from their push campaigns. This is especially true for devices that are in battery saver mode or cannot be reached due to inactivity. “RenderMax is a testament to our continued commitment towards product development and innovation. Low render rates stifle the true potential of mobile push notifications. We are confident that with RenderMax, brands will be able to harness the full power of push notifications. What’s interesting is that we are offering RenderMax to all customers at no additional cost to any brand that wants to try it out.” said Anand Jain, Co-Founder & Chief Product Officer, CleverTap. Betterhalf, India's first and only marriage super app was provided an early access to RenderMax and their push notification render rates more than doubled! Shankar Krishnamurthy, Group Product Manager, Betterhalf said, “At Betterhalf, mobile push notifications are critical for our business. With CleverTap’s innovative RenderMax solution our push notification render rates have skyrocketed to 85%.” RenderMax powers up the render rates of customers’ push notifications, amplifies the push notification reach, and maximizes user engagement. Enhancing the reach of push notifications can help CleverTap customers lower costs, increase engagement and conversion rates, and reduce churn. “The CleverTap platform has a great breadth of capabilities, and this innovative mobile push solution will certainly help them stay much ahead of the competition,” Shankar added. CleverTap RenderMax works with Android OEMs such as Oppo, Xiaomi, Vivo, One Plus, POCO, Realme, and Samsung. About CleverTap CleverTap is the World's #1 Retention Cloud that helps app-first brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ - the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 1500 customers, including Gojek, ShopX, Electronic Arts, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

December 07, 2022 05:07 AM Eastern Standard Time

Matthew Coleman Joins AmeriLife as Vice President of Annuity and Life Product Innovation

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that Matthew Coleman has joined the company as vice president of Annuity and Life Product Innovation. In this newly created role, which will report to AmeriLife’s Senior Vice President of Product Innovation Brad Shelton, Coleman will partner with the company’s valued carrier partners to expand AmeriLife’s proprietary life insurance and annuity offerings to better meet the increasing demands of the company’s affiliates and their agents and clients. “Matt brings a powerful combination of actuarial expertise and leadership experience within both carrier and distribution organizations,” said Shelton. “His addition comes at a perfect time given AmeriLife’s continued growth in the life and annuities space. We’re thrilled to have him join our team.” Coleman brings nearly 30 years of industry experience to AmeriLife, most recently serving as a director at Willis Towers Watson, where he led business and product development, actuarial support and distribution strategy for the fixed, indexed and variable annuity markets. Previous to Willis Towers Watson, Coleman worked in progressively senior positions for BMA Insurance Company and financial services company CreativeOne. He also co-founded the Ideal Producers Group, where he spearheaded the actuarial department and led product innovation, design and marketing. Coleman, who holds Bachelor’s and Master’s degrees from the University of Kansas, is also a fellow of the Society of Actuaries and a member of the American Academy of Actuaries. “At a time of increased distribution aggregation in the life and annuity markets, the integration of product development and distribution is a key business accelerator,” said Coleman. “Quality and insightful product development turns insurer relationships into long-lasting partnerships and maximizes the value delivered up and down the vertical. I look forward to helping deliver that on behalf of AmeriLife.” “Matt’s appointment comes at a critical time of increasing demand for solutions that deliver on consumers’ total financial wellbeing," added Pat Fleming, executive vice president of Product Innovation and corporate actuary. “We look forward to Matt’s contributions with the development of proprietary life and annuity products, which will expand our growing product portfolio and provide unique solutions for our carrier partners as well as our marketers, agents and consumers.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

December 06, 2022 01:00 PM Eastern Standard Time

LectureLinx and PAYCE Announce a Global Expansion Through a Worldwide Exclusive Licensing Agreement to Combine Technologies and Services for the Pharmaceutical Industry

LectureLinx

LectureLinx, a leader in compliance technologies for the pharmaceutical and life science industries, and PAYCE, a leading pharmaceutical technology provider for healthcare professionals (HCPs) and healthcare organizations (HCOs) in Europe, have agreed to an exclusive global license to integrate key PAYCE technologies and services into the LectureLinx platform and systems in a worldwide initiative to transform how healthcare practitioners and the pharmaceutical industry collaborate. In the last decade pharmaceutical and life science companies have adopted new transparency reporting requirements across different countries, whilst seeking to minimise the impacts on the HCP and ensuring that their systems and processes remain highly effective. More and more companies are now fully focused on the HCP experience. With continued operational challenges, reporting, tracking, audit and more, LectureLinx and PAYCE saw the opportunity to combine forces to solve both problems. Based in the U.S., LectureLinx will develop and commercialize the multi-functional PAYCE platform, which has an established reputation across the European pharma market. The purpose-built industry platform offers a new standard in compliance technologies for the pharmaceutical industry, as well as proven solutions, which include streamlined contracting and faster HCP payments, as well as strengthening disclosure reporting, while recognizing regional differences across international markets. The two companies will combine their expertise and experience across different locations and their understanding of local markets to operate as a single global provider, delivering expanded offerings and reach, a broader set of solutions, and increased benefits to existing and future clients. “Years of real-world market experience allow LectureLinx and PAYCE to combine forces to make this bold and brave move. Together, we provide a unique, fully integrated solution across the globe, which no other provider can offer or match,” said LectureLinx Founder and CEO Ellen Varelas. “It’s challenging to navigate the pharmaceutical markets both in the U.S. and EU. But together, with integrated solutions and strategies and future investment in development, we will enable our pharmaceutical clients to offer unparalleled experiences for healthcare providers and organizations.” “We are leveraging our shared synergies and combining our solutions to fulfill a global need for pharma and, more importantly, a better experience for HCPs and HCOs worldwide,” said PAYCE Founder and CEO David Bloomfield. “Every business that is looking to strengthen its compliance and improve HCP engagement on a global scale will benefit.” LectureLinx’s global headquarters will remain in the US. The European headquarters will be located in the UK. To learn more, please visit: www.lecturelinx.com About LectureLinx Founded in 2001, LectureLinx is a technology company providing pharmaceutical and life science companies with an ecosystem of innovative products and platforms designed to improve operational efficiency and reduce risk with the confidence that processes are compliant, auditable, and reportable. LectureLinx’s solutions are imminently scalable and supported by over 20 years of real-world expertise and hands-on market experience. As trusted advisors and solution providers, LectureLinx provides world-class and fully integrated solutions while ensuring a best-in-class experience for end users. Learn more at lecturelinx.com About PAYCE PAYCE is a dedicated, purpose-built portal offering a new standard in compliance technologies for the pharmaceutical industry. It is also a specialist contracting and payment tool that offers an unrivalled experience for pharmaceutical companies, healthcare professionals and healthcare organisations. PAYCE streamlines contracting and payment processes, removing complexity so that users can focus on execution. PAYCE is used by leading pharmaceutical companies and thousands of HCPs and HCOs. Contact Details Jennifer Cronin lecturelinx@trustrelations.agency Carole Ayemaung carole.ayemaung@cofinitive.com

December 06, 2022 09:01 AM Eastern Standard Time

Healthcare